In the appraisal consultation document published on the NICE website, the appraisal committee's preliminary recommendation states:
Daclizumab is not recommended within its marketing authorisation for treating relapsing forms of multiple sclerosis in adults... Read more - http://www.ms-uk.org/nice-says-no-dacli ... yta-051016
NICE says no to daclizumab (Zinbryta)
NICE says no to daclizumab (Zinbryta)
MS-UK - http://www.ms-uk.org/
-
HarryZ
- Family Elder
- Posts: 2572
- Joined: Tue May 25, 2004 2:00 pm
- Location: London, ON, Canada
- Contact:
Re: NICE says no to daclizumab (Zinbryta)
Daclizumab is an experimental drug treatment being developed for relapsing remitting MS. It is taken as an injection under the skin, once a month. In clinical trials, daclizumab reduced relapse rates by approximately 50% compared to placebo and by 45% compared to beta interferon. The drug was licensed in Europe in July 2016.MSUK wrote:In the appraisal consultation document published on the NICE website, the appraisal committee's preliminary recommendation states:
Daclizumab is not recommended within its marketing authorisation for treating relapsing forms of multiple sclerosis in adults... Read more - http://www.ms-uk.org/nice-says-no-dacli ... yta-051016
Now what does this info say about beta inferferon?!!! Only a 5 % better result than by taking nothing?